Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement
- Responses address selected shareholder-submitted questions and provide additional investor context
- Exhibit 99.1 contains the written responses and is available through Clover’s investor relations website
Item EX-99.1 · Exhibit EX-99.1
- Management sees meaningful earnings leverage through 2028 as 2025-2026 cohorts, roughly half of membership, mature into stronger economics
- 3Q26 membership reached ~159k, leaving fixed-cost absorption potential and a stated 100-150 basis-point 2026 Adjusted SG&A improvement target
- Counterpart Assistant evidence includes 18% fewer heart-failure hospitalizations, 25% fewer readmissions, and ~1,500-basis-point historical MCR advantage
- Counterpart’s commercial opportunity remains difficult to value: contracted lives, implementation schedules, and recurring-revenue outlook withheld
- New Jersey individual non-SNP share rose from roughly 20% to 31%, supporting continued growth beyond competitor-driven disruption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.